Interferon-α
1
Reactions 657 - 28 Jun 1997 S Interferon-α Emergence of new clonal abnormalities in patients with chronic myeloid leukaemia: 3 case reports Three patients with Philadelphia chromosome-positive chronic myeloid leukaemia (CML) developed new cytogenetic abnormalities after they had achieved complete cytogenetic remission with interferon-α therapy. The first patient, a 72-year-old man, started treatment with recombinant interferon-α 5 MU/m 2 /day and a cytogenetic complete remission was achieved after 6 months. Interferon-α was stopped after approximately 40 months because of durable cytogenetic response and moderate symptoms of Raynaud’s phenomenon. Approximately 20 months later, he developed chromosomal abnormalities involving chromosome 5. After a further 2 years, a myelodysplastic syndrome was seen. Subsequent marrow studies revealed transformation to acute myeloid leukaemia, still without any detectable Philadelphia chromosome abnormality. [Patient outcome not stated.] The second patient, a 62-year-old woman, was treated with interferon-α 5 MU/m 2 /day and cytogenetic complete remission was achieved after 13 months of therapy. Interferon-α was stopped after another 18 months because she developed Coombs-positive autoimmune haemolytic anaemia. 61 months after the cessation of interferon-α, she developed a myeloproliferative syndrome with 18p11 chromosomal abnormalities. [Patient outcome not stated.] The third patient, a 59-year-old man, was treated with interferon-α 5 MU/m 2 /day and cytarabine and a cytogenetic complete remission was achieved after 6 months of treatment. Approximately 2 years after the start of interferon-α therapy, he developed a chromosome 11 abnormality. There were no haematological complications and treatment with interferon-α was continued. [Patient outcome not stated.] Author comment: ‘These findings stress the importance of long-term monitoring of patients with CML or other cancers who undergo new treatments that alter the previously charted course of their disease, in order to observe potential disease or new treatment-related manifestations.’ Fayad L, et al. Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases. Leukemia 11: 767-771, May 1997 - USA 800535142 1 Reactions 28 Jun 1997 No. 657 0114-9954/10/0657-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Interferon-α
Reactions 657 - 28 Jun 1997
SInterferon-αEmergence of new clonal abnormalities in patientswith chronic myeloid leukaemia: 3 case reports
Three patients with Philadelphia chromosome-positivechronic myeloid leukaemia (CML) developed new cytogeneticabnormalities after they had achieved complete cytogeneticremission with interferon-α therapy.
The first patient, a 72-year-old man, started treatment withrecombinant interferon-α 5 MU/m2/day and a cytogeneticcomplete remission was achieved after 6 months. Interferon-αwas stopped after approximately 40 months because ofdurable cytogenetic response and moderate symptoms ofRaynaud’s phenomenon. Approximately 20 months later, hedeveloped chromosomal abnormalities involvingchromosome 5. After a further 2 years, a myelodysplasticsyndrome was seen. Subsequent marrow studies revealedtransformation to acute myeloid leukaemia, still without anydetectable Philadelphia chromosome abnormality. [Patientoutcome not stated.]
The second patient, a 62-year-old woman, was treated withinterferon-α 5 MU/m2/day and cytogenetic completeremission was achieved after 13 months of therapy.Interferon-α was stopped after another 18 months becauseshe developed Coombs-positive autoimmune haemolyticanaemia. 61 months after the cessation of interferon-α, shedeveloped a myeloproliferative syndrome with 18p11chromosomal abnormalities. [Patient outcome not stated.]
The third patient, a 59-year-old man, was treated withinterferon-α 5 MU/m2/day and cytarabine and a cytogeneticcomplete remission was achieved after 6 months of treatment.Approximately 2 years after the start of interferon-α therapy,he developed a chromosome 11 abnormality. There were nohaematological complications and treatment with interferon-αwas continued. [Patient outcome not stated.]
Author comment: ‘These findings stress the importance oflong-term monitoring of patients with CML or other cancerswho undergo new treatments that alter the previously chartedcourse of their disease, in order to observe potential disease ornew treatment-related manifestations.’Fayad L, et al. Emergence of new clonal abnormalities following interferon-alphainduced complete cytogenetic response in patients with chronic myeloid leukemia:report of three cases. Leukemia 11: 767-771, May 1997 - USA 800535142
1
Reactions 28 Jun 1997 No. 6570114-9954/10/0657-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
